ViroPharma Gets Good News And Bad News On Cinryze From FDA

sBLA for acute angioedema treatment gets a “complete response,” putting Cinryze into the losers’ bracket contesting for the first U.S. acute HAE approval. Drug’s prophylactic labeling, meanwhile, is amended to allow self-administration.